Activities

2024.11.01

How to Verify Your Cre-lox Model

Now that the genetically engineered mice that carry a Cre-conditional (“floxed”) allele in target gene are at your hand. And the mice are supposed to express Cre in target tissue. The validation of your Cre-lox model become very indispensable, so here we advise you of some essential steps. Genotype the mice When unexpected phenotypes are observed during your working with mice, the […]

2024.11.01

These Mice Are About to Go Viral Because of the Nobel Prize!

The 2024 Nobel Prize in Physiology or Medicine has been announced, and the winners are two American scientists, Victor Ambros and Gary Ruvkun, in recognition of their discovery of microRNA and its role in post-transcriptional gene regulation. This discovery is considered a major breakthrough following the central dogma of molecular biology. The Nobel Committee stated […]

2024.11.01

Enhancing Your Research: How GenoBioTX’s Gene Editing Technology Empowers Research Breakthroughs

Registration link: https://www.eventbrite.com/e/genobiotx-monthly-webinar-tickets-1053785844829 Date: Wednesday, Oct 30th, 2024; 11:00 am PDT, or 2:00 pm EDT Webinar Highlights: This seminar will introduce GenoBioTX’s gene editing platform and technology, highlighting how these techniques can enhance your research projects. We will cover the history of genome editing, provide an overview of GenoBioTX’s gene editing platform and technology, and present […]

2024.11.01

Why IL-2 Still Holds Promise in Therapeutics of Cancer and Autoimmunity

Aclidineleukin (high-dose IL-2) is the first FDA-approved cancer immunotherapy for metastatic renal cell carcinoma (RCC) and melanoma, but the widespread clinical use of aclidinein has been limited by its short half-life, serious side effects, and simultaneous stimulation of Treg activation. With the breakthrough of studies of immune checkpoint inhibitors, IL-2-based therapeutics has regained widespread attention, […]

2024.11.01

CCR8: the Next Promising Immune Checkpoint for Antitumor Drugs Development

CCR8, as a novel immune checkpoint in tumor microenvironment, was hotly discussed during 2022 AACR conference. Since then, numerous prestigious pharmaceutical corporations have shifted their attention to CCR8, previously almost unknown. You may wonder why CCR8 gave rise to so strong interest of pharmaceutical industry. Just follow us to have a quick review of CCR8, […]

2024.11.01

Webinar on Advances in Antibody-Drug Conjugates (ADCs) Development & Preclinical Models

Join our webinar on June 26th to explore the development and preclinical evaluation of Antibody-Drug Conjugates (ADCs), focusing on their components, mechanisms, and the selection of effective preclinical models for advancing targeted cancer therapies. Date: · Wednesday, June 26th, 2024; 2:00 pm EDT or 11:00 am PDT Webinar Highlights: Meet Our Speaker: Dr. Hua Wei […]

2024.11.01

New Service Launch: Mouse Bone Metastasis Cancer Model and Pain-Related Behavior Assessment!

What is Bone Cancer Pain?  Cancer-induced Bone Pain (CIBP) or Bone Cancer Pain (BCP) is a type of pain caused by the invasion of tumors (such as primary bone tumors or bone metastases from breast cancer, prostate cancer, bladder cancer, lung cancer, etc.) into the bones [1]. This pain can severely impact a patient’s mental state […]

2024.11.01

Overcome the Hurdle to Generate High Affinity and Diversity Antibodies to Self- or High Homology Antigens

Registration link:  https://us06web.zoom.us/webinar/register/WN_zp48kyBhSH2rHpm_adFNIw Date: Webinar Highlights: This webinar will explore various methods for generating monoclonal antibodies, emphasizing the challenges of producing high-affinity antibodies to self or highly homologous antigens. Traditional methods, like in vitro screening and hybridoma-derived antibodies post-immunization, are cost-effective but struggle with these targets. Alternative approaches, such as fusion expression with T cell […]

Email Back to top